#ASCO14 - Poster: A randomized, open-label phase 2a study evaluating quantified bone scan response following treatment with radium-223 dichloride alone or in combination with abiraterone acetate or enzalutamide...

CHICAGO, IL USA (UroToday.com) - Full Title: #ASCO14 - Poster: A randomized, open-label phase 2a study evaluating quantified bone scan response following treatment with radium-223 dichloride alone or in combination with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer who have bone metastases

Presented by Daniel Petrylak, MD,¹ Julie A. Rosenberg, MD,² Vittorio Luigi Garosi, MD, PhD,³ Jonathan Siegel,² and Jonathan Goldin, MD⁴ at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

Click HERE to listen to an exclusive interview with Daniel Petrylak, MD, one of the authors of the study

¹Yale Cancer Center, New Haven, CT USA
²Bayer HealthCare Pharmaceuticals, Inc., Whippany NJ, USA
³Bayer S.p.A., Milan, Italy
⁴UCLA Radiology Science, Los Angeles, CA USA